NCT06058793 2026-01-09Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated LiposarcomaBoehringer IngelheimPhase 3 Completed138 enrolled
NCT06370871 2024-07-17Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue SarcomaBoehringer IngelheimPhase 3 Withdrawn